Delving into the Latest Updates on Propantheline Bromide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Propantheline bromide (JP17/USP/INN)

+ [2]

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Nervous System DiseasesDigestive System DisordersSkin and Musculoskeletal Diseases+ [2]

Active Indication

Peptic UlcerUrinary Bladder, NeurogenicUrinary Incontinence+ [12]

Inactive Indication

Gastrospasm

Originator Organization

G.D. Searle Co.

Active Organization

Pfizer Japan, Inc.

Arrotex Pharmaceuticals Pty Ltd.

Inactive Organization

Shire Development LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (02 Apr 1953),

GastrospasmHyperhidrosisPeptic Ulcer

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H30BrNO3

InChIKeyXLBIBBZXLMYSFF-UHFFFAOYSA-M

CAS Registry50-34-0

The purpose of this study is to compare the stone clearance rate treated with different drugs after ESWL in urinary calculus,These drugs are often used in urinary calculus,such as progesterone,tamsulosin,propantheline Bromide and nifedipine.In these study the investigators want to investigate different effect of these drugs use to treat urinary calculus after ESWL.

Start Date01 Oct 2009

Sponsor / Collaborator

Chongqing Medical University

100 Clinical Results associated with Propantheline Bromide

Login to view more data

100 Translational Medicine associated with Propantheline Bromide

Login to view more data

100 Patents (Medical) associated with Propantheline Bromide

Login to view more data

795

Literatures (Medical) associated with Propantheline Bromide

01 Jun 2025·Bioorganic & Medicinal Chemistry Letters

Design, synthesis, and activity evaluation of C-8 arylated luteolin derivatives as influenza endonuclease inhibitors

Article

Author: Reiberger, Róbert ; Konvalinka, Jan ; Machara, Aleš ; Majer, Pavel ; Kožíšek, Milan ; Tsalyy, Artem ; Kráľ, Michal

The polymerase acidic (PA) subunit of the influenza virus, an endonuclease of the RNA-dependent RNA polymerase, represents a viable target for anti-influenza therapies, as evidenced by the efficacy of the FDA-approved drug Xofluza. A characteristic feature of endonuclease inhibitors is their ability to chelate Mg²⁺ or Mn²⁺ ions within the enzyme's catalytic site. Previously, our studies identified luteolin and its C-8-glucoside orientin as potent endonuclease inhibitors. This report details our subsequent investigation into the structural modifications of the phenyl moiety attached to the C-8 position of luteolin. The inhibitory potencies (IC₅₀ values) quantified with AlphaScreen technology indicated that substituting the C-8 glucose moiety of orientin resulted in compounds with comparable inhibitory potency. From a series of eighteen compounds, acid 12 with 3-carboxylphenyl moiety at the C-8 position was the most potent inhibitor with nanomolar potency.

01 Feb 2025·Biopharmaceutics & Drug Disposition

In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules

Article

Author: Kato, Masami ; Mukai, Tadashi ; Suzuki, Yuji ; Kano, Mayumi ; Miyake, Masateru

ABSTRACTEstablishment of a suitable animal model to evaluate sustained release (SR) formulations is very important because it reduces the development time of SR formulations. Beagle dogs are often used to evaluate prototype formulations since they can be directly administered powder, such as drug substance. However, the physiological condition of dogs is very different to that of humans. Therefore, the benefits of utilizing beagle dogs for the evaluation of modified release formulations such as sustained release formulations and enteric‐coated formulations are doubtful. To clarify the best animal and/or experimental technique for the evaluation of modified release formulations, we investigated dipyridamole pharmacokinetics from prototype sustained release granules by utilizing beagle dogs, propantheline bromide‐treated (PBT) beagle dogs, and miniature pigs. In normal dogs, the intestinal absorption and sustained release effect of dipyridamole decreased in the 20 mg sustained release granule. However, in PBT dogs, a sustained release effect was observed in the 45 mg sustained release granule, and its bioavailability was also maintained. Accordingly, PBT dogs could be the best to evaluate sustained release formulations such as tablets and granules, and the use of miniature pigs might be better to evaluate granules with equal to or less than 1 mm diameter.

01 Dec 2023·BMJ Supportive & Palliative Care

Oral propantheline in palliative care: two further cases – bowel/bladder spasm and high-output stoma

Letter

Author: Banting, Mark

100 Deals associated with Propantheline Bromide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00481	Propantheline Bromide	A03AB05	DBSALT000225

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peptic Ulcer	Australia	Arrotex Pharmaceuticals Pty Ltd.	17 Jun 2013
Urinary Bladder, Neurogenic	Australia	Arrotex Pharmaceuticals Pty Ltd.	17 Jun 2013
Urinary Incontinence	Australia	Arrotex Pharmaceuticals Pty Ltd.	17 Jun 2013
Biliary Dyskinesia	Japan	Pfizer Japan, Inc.	12 Nov 1976
Duodenal Ulcer	Japan	Pfizer Japan, Inc.	12 Nov 1976
Enteritis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Enuresis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Gastritis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Hyperhidrosis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Irritable Bowel Syndrome	Japan	Pfizer Japan, Inc.	12 Nov 1976
Nocturnal Enuresis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Pancreatitis	Japan	Pfizer Japan, Inc.	12 Nov 1976
Pylorospasm	Japan	Pfizer Japan, Inc.	12 Nov 1976
Stomach Diseases	Japan	Pfizer Japan, Inc.	12 Nov 1976
Stomach Ulcer	Japan	Pfizer Japan, Inc.	12 Nov 1976